666 related articles for article (PubMed ID: 23422369)
21. Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.
Tateno A; Sakayori T; Kim WC; Honjo K; Nakayama H; Arakawa R; Okubo Y
Int J Neuropsychopharmacol; 2018 Jun; 21(6):522-527. PubMed ID: 29346639
[TBL] [Abstract][Full Text] [Related]
22. Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: a PET study.
Chou YH; Halldin C; Farde L
Synapse; 2000 Nov; 38(2):138-43. PubMed ID: 11018787
[TBL] [Abstract][Full Text] [Related]
23. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.
Vernaleken I; Janouschek H; Raptis M; Hellmann S; Veselinovic T; Bröcheler A; Boy C; Cumming P; Hiemke C; Rösch F; Schäfer WM; Gründer G
Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299
[TBL] [Abstract][Full Text] [Related]
24. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole.
Nyberg S; Olsson H; Nilsson U; Maehlum E; Halldin C; Farde L
Psychopharmacology (Berl); 2002 Jun; 162(1):37-41. PubMed ID: 12107615
[TBL] [Abstract][Full Text] [Related]
25. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P
Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
[TBL] [Abstract][Full Text] [Related]
26. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients.
Farde L; Suhara T; Nyberg S; Karlsson P; Nakashima Y; Hietala J; Halldin C
Psychopharmacology (Berl); 1997 Oct; 133(4):396-404. PubMed ID: 9372541
[TBL] [Abstract][Full Text] [Related]
27. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
[TBL] [Abstract][Full Text] [Related]
28. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of dopamine D
Sakayori T; Tateno A; Arakawa R; Kim WC; Okubo Y
Psychopharmacology (Berl); 2021 May; 238(5):1343-1350. PubMed ID: 33180175
[TBL] [Abstract][Full Text] [Related]
30. PET studies of D2-receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans.
Cervenka S; Varrone A; Fransén E; Halldin C; Farde L
Synapse; 2010 Jun; 64(6):478-85. PubMed ID: 20175222
[TBL] [Abstract][Full Text] [Related]
31. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.
Mizrahi R; Rusjan P; Agid O; Graff A; Mamo DC; Zipursky RB; Kapur S
Am J Psychiatry; 2007 Apr; 164(4):630-7. PubMed ID: 17403977
[TBL] [Abstract][Full Text] [Related]
32. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.
Catafau AM; Suarez M; Bullich S; Llop J; Nucci G; Gunn RN; Brittain C; Laruelle M;
Neuroimage; 2009 Jun; 46(2):447-58. PubMed ID: 19233294
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
34. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
[TBL] [Abstract][Full Text] [Related]
35. The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity.
Suzuki H; Gen K
Hum Psychopharmacol; 2010; 25(4):342-6. PubMed ID: 20521325
[TBL] [Abstract][Full Text] [Related]
36. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
Int J Neuropsychopharmacol; 2011 Feb; 14(1):83-9. PubMed ID: 20860881
[TBL] [Abstract][Full Text] [Related]
37. Low convergent validity of [
Freiburghaus T; Svensson JE; Matheson GJ; Plavén-Sigray P; Lundberg J; Farde L; Cervenka S
Neuroimage; 2021 Feb; 226():117523. PubMed ID: 33144221
[TBL] [Abstract][Full Text] [Related]
38. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
39. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Kapur S; Zipursky R; Jones C; Remington G; Houle S
Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
[TBL] [Abstract][Full Text] [Related]
40. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
